Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

5.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Oak to Wine: Evolution, Admixture, and Adaptation of California and British Columbia Saccharomyces cerevisiae Wine Strains.

Genome biology and evolution·2026
Same author

FloTrac-Guided Hemodynamic Monitoring Optimizes ERAS Implementation in Coronary Artery Bypass Surgery: A Retrospective Three-Phase Analysis.

Journal of cardiothoracic and vascular anesthesia·2026
Same author

Shock-scattering micro-histotripsy-aided fine needle aspiration for enhanced biomarker profiling and cytopathology.

Nature communications·2026
Same author

Liver-Targeted AAV-DJ-hCBS Therapy Achieves Long-Term Correction of Metabolic Imbalance in CBS-Deficient Mice.

International journal of molecular sciences·2026
Same author

Revealing abrupt transitions from goal-directed to habitual behavior.

Nature communications·2026
Same author

Dexamethasone Suppresses Already Low Estrogen Receptor Levels in Meningiomas.

International journal of molecular sciences·2026
Same journal

DNA methylation-mediated silencing of STAT5A drives breast cancer metastasis via dual regulation of EMT and immunosuppressive microenvironment.

Oncogene·2026
Same journal

LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.

Oncogene·2026
Same journal

A novel circSLIT2-encoded SLIT2 isoform suppresses neural invasion in gastric cancer.

Oncogene·2026
Same journal

The miR-302 family suppresses tumor growth in tongue squamous cell carcinoma by directly targeting P65.

Oncogene·2026
Same journal

MOV10 suppresses circRNA biogenesis by disrupting reverse complementary matches structure to drive hepatocarcinogenesis.

Oncogene·2026
Same journal

HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer.

Oncogene·2026
See all related articles

Related Experiment Video

Updated: May 8, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.6K

Multiple anti-tumor programs are activated by blocking BAD phosphorylation.

John Maringa Githaka1, Raven Kirschenman2, Namrata Patel2

  • 1Department of Biochemistry, University of Alberta, Edmonton, AB, Canada. maringa@ualberta.ca.

Oncogene
|May 2, 2025
PubMed
Summary
This summary is machine-generated.

Unphosphorylated BAD protein inhibits breast cancer progression and metastasis by activating anti-tumor pathways. Targeting ERK to dephosphorylate BAD presents a potential future therapeutic strategy for breast cancer.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K
Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

8.5K

Related Experiment Videos

Last Updated: May 8, 2025

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.6K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K
Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

8.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • The Bcl-2 family member BAD regulates apoptosis and cell migration.
  • BAD's anti-cancer activity is linked to its unphosphorylated state at key serine residues (S75, S99, S118).
  • Cancer often hijacks normal developmental pathways, suggesting a potential role for BAD in tumor progression.

Purpose of the Study:

  • To investigate the role of BAD phosphorylation in breast cancer progression.
  • To determine if unphosphorylated BAD exhibits anti-tumor activity.
  • To identify therapeutic targets for modulating BAD activity in breast cancer.

Main Methods:

  • Generated PyMT-Bad knockout and phosphorylation-deficient (3SA) mouse models of breast cancer.
  • Utilized transcriptomics to analyze anti-tumor programs.
  • Performed kinase screens to identify BAD kinases.
  • Correlated BAD phosphorylation status with clinical patient survival data.

Main Results:

  • Preventing BAD phosphorylation significantly reduced breast cancer progression and metastasis.
  • The BAD 3SA mutation activated anti-tumor programs, including apoptosis and inflammation, and diminished cell migration.
  • Unphosphorylated BAD levels correlated with improved patient survival.
  • ERK was identified as the major BAD kinase in breast cells, and its inhibition reduced tumoroid invasion.

Conclusions:

  • Unphosphorylated BAD possesses latent anti-tumor activity that impedes breast cancer progression.
  • Targeting ERK to dephosphorylate BAD represents a promising future therapeutic avenue for breast cancer treatment.